11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: not found
          • Article: not found
          Is Open Access

          Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

          The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (Chinese Society of Clinical Oncology), Korea (Korean Association for Clinical Oncology), Malaysia (Malaysian Oncological Society), Singapore (Singapore Society of Oncology) and Taiwan (Taiwan Oncology Society). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

            Background In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus chemotherapy improved median overall survival by 2.7 months in patients with human epidermal growth factor receptor 2 (HER2)-positive [immunohistochemistry (IHC) 3+/fluorescence in situ hybridization-positive] gastric/gastroesophageal junction cancer compared with chemotherapy alone (hazard ratio 0.74). Post hoc exploratory analyses in patients expressing higher HER2 levels (IHC 2+/fluorescence in situ hybridization-positive or IHC 3+) demonstrated a 4.2-month improvement in median overall survival with trastuzumab (hazard ratio 0.65). The ToGA study provides the largest screening dataset available on HER2 overexpression/amplification in this indication. We further analyzed correlation(s) of HER2 overexpression/amplification with clinical and epidemiological factors. Methods HER2-positivity was analyzed by histological subtype, tumor location, geographic region, and specimen type. Exploratory efficacy analyses were performed. Results The HER2-positivity rate was 22.1 % across analyzed tumor samples. Rates were similar between European and Asian patients (23.6 % vs. 23.9 %), but higher in intestinal- vs. diffuse-type (31.8 % vs. 6.1 %), and gastroesophageal junction cancer versus gastric tumors (32.2 % vs. 21.4 %). Across all IHC scores, variability in HER2 staining (≤30 % stained cells) was observed in almost 50 % of cases, with increasing rates in lower IHC categories, and did not affect treatment outcome. The polysomy rate was 4 %. Conclusions HER2 expression varies by tumor location and type. All patients with advanced gastric or gastroesophageal junction cancer should be tested for HER2 status, preferably using IHC initially. Due to the unique characteristics of gastric cancer, specific testing/scoring guidelines should be adhered to. Electronic supplementary material The online version of this article (doi:10.1007/s10120-014-0402-y) contains supplementary material, which is available to authorized users.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients.

              , , C Dykewicz (2001)
              This article contains highlights of "Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients: Recommendations of the CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation," which was published in the Morbidity and Mortality Weekly Report. There are sections on the prevention of bacterial, viral, fungal, protozoal, and helminth infections and on hospital infection control, strategies for safe living following transplantation, immunizations, and hematopoietic stem cell safety. The guidelines are evidence-based, and prevention strategies are rated by both the strength of the recommendation and the quality of evidence that supports it. Recommendations are given for preventing cytomegalovirus disease with prophylactic or preemptive gancyclovir, herpes simplex virus disease with prophylactic acyclovir, candidiasis with fluconazole, and Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole. Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients.
                Bookmark

                Author and article information

                Journal
                Annals of Oncology
                Oxford University Press (OUP)
                0923-7534
                1569-8041
                January 2019
                January 01 2019
                November 22 2018
                January 2019
                January 01 2019
                November 22 2018
                : 30
                : 1
                : 34-43
                Affiliations
                [1 ]Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
                [2 ]University Cancer Center Leipzig, Leipzig
                [3 ]1st Department of Medicine (Hematology and Medical Oncology), University Hospital Leipzig, Leipzig, Germany
                [4 ]Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
                [5 ]Department of Medical Oncology, University of Ioannina, Ioannina, Greece
                [6 ]Department of Comprehensive Clinical Oncology, Kyushu University, Fukuoka, Japan
                [7 ]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
                [8 ]Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
                [9 ]Department of Radiotherapy & Oncology, General Hospital, Kuala Lumpur, Malaysia
                [10 ]Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
                [11 ]National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
                [12 ]Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
                [13 ]Department of Oncology, Tongji University affiliated East Hospital, Shanghai, China
                [14 ]Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
                [15 ]Department of Clinical Oncology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
                [16 ]Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
                [17 ]Department of Oncology, National Taiwan University Hospital, Taipei
                [18 ]National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei, Taiwan
                [19 ]Department of Clinical Oncology, School of Medicine, St. Marianna University, Kawasaki
                [20 ]Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa
                [21 ]Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan
                [22 ]Digestive Oncology, University Hospitals Leuven, Leuven, Belgium
                [23 ]Department of Experimental Medicine – Medical Oncology, Università degli Studi della Campania L Vanvitelli, Napoli, Italy
                [24 ]Department of Oncology, University of Cambridge, Cambridge, UK
                [25 ]Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg, Germany
                [26 ]Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan
                [27 ]Medical Oncology Department, Vall d' Hebron University Hospital, Vall d'Hebron Institute of Oncology (V.H.I.O.), Barcelona, Spain
                [28 ]ESMO, Lugano, Switzerland
                Article
                10.1093/annonc/mdy498
                30475943
                721b91e8-a71d-46d7-87bf-18e6ebc3785c
                © 2018

                https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

                History

                Comments

                Comment on this article